{"id":3757,"date":"2025-05-29T10:06:25","date_gmt":"2025-05-29T14:06:25","guid":{"rendered":"https:\/\/www.accessforkidscancer.ca\/?post_type=theme-project&#038;p=3757"},"modified":"2025-12-12T12:16:08","modified_gmt":"2025-12-12T17:16:08","slug":"lessai","status":"publish","type":"theme-project","link":"http:\/\/www.accessforkidscancer.ca\/fr\/projects\/lessai\/","title":{"rendered":"L\u2019essai <span> AALL2131 <\/span>"},"content":{"rendered":"<p>La leuc\u00e9mie lymphoblastique aigu\u00eb (LLA-B) \u00e0 chromosome Philadelphie positif (Ph<sup>+<\/sup>) et la LLA-B de classe ABL de type Ph repr\u00e9sentent pr\u00e8s de 10\u00a0% de tous les cas de LLA p\u00e9diatrique et sont historiquement associ\u00e9es \u00e0 des r\u00e9sultats inf\u00e9rieurs. Ces sous-types partagent une expression g\u00e9nique et des profils cliniques similaires, une faible r\u00e9ponse \u00e0 la chimioth\u00e9rapie traditionnelle et une sensibilit\u00e9 aux inhibiteurs de la tyrosine kinase (ITK) ciblant l\u2019ABL comme l\u2019imatinib ou le dasatinib.<\/p>\n<p>Dans le cas de la LLA-B Ph<sup>+<\/sup> , l\u2019administration pr\u00e9coce et continue d\u2019ITK en association avec un squelette de chimioth\u00e9rapie intensive a consid\u00e9rablement am\u00e9lior\u00e9 les taux de r\u00e9ponse et la survie sans \u00e9v\u00e9nement (SSE), en plus d\u2019\u00e9liminer le besoin d\u2019une greffe de cellules souches h\u00e9matopo\u00ef\u00e9tiques en premi\u00e8re r\u00e9mission chez la plupart des enfants. Cette approche \u00e0 ciblage mol\u00e9culaire a r\u00e9volutionn\u00e9 le paradigme de traitement pour ces patients dont la SSE \u00e0 cinq ans et la survie globale sont en moyenne de 60\u00a0% et de 80\u00a0%, respectivement. De plus, d\u2019apr\u00e8s les rapports de petites cohortes de patients, une strat\u00e9gie de traitement similaire a \u00e9galement donn\u00e9 des r\u00e9sultats favorables pour les patients atteints de LLA-B de type Ph de classe ABL, bien qu\u2019un sch\u00e9ma th\u00e9rapeutique standard n\u2019ait pas encore \u00e9t\u00e9 \u00e9tabli pour ces patients. N\u00e9anmoins, au cours des deux derni\u00e8res d\u00e9cennies, malgr\u00e9 l\u2019am\u00e9lioration des r\u00e9sultats \u00e0 l\u2019\u00e8re de l\u2019ITK, les enfants atteints de LLA Ph<sup>+<\/sup> continuent de souffrir de taux plus \u00e9lev\u00e9s de rechute, de toxicit\u00e9s importantes li\u00e9es au traitement et d\u2019effets secondaires \u00e0 long terme accrus que les patients atteints de LLA Ph. Par cons\u00e9quent, il reste n\u00e9cessaire d\u2019optimiser le traitement.<\/p>\n<p>L\u2019essai AALL2131 du Children\u2019s Oncology Group (COG) est une \u00e9tude pilote internationale qui examinera les avantages de la combinaison de la chimioth\u00e9rapie standard avec l\u2019ITK et le blinatumomab sur la SSE \u00e0 trois ans chez les patients nouvellement diagnostiqu\u00e9s atteints de LLA-B de type Ph de classe Ph<sup>+<\/sup> ou ABL. Apr\u00e8s l\u2019induction, tous les patients recevront un ITK continu avec un squelette de chimioth\u00e9rapie modifi\u00e9 qui comprend trois cycles de blinatumomab. Cependant, cet essai utilise clonoSEQ, un essai de s\u00e9quen\u00e7age de nouvelle g\u00e9n\u00e9ration (SNG) d\u2019Adaptive Biotechnologies, pour d\u00e9tecter et surveiller la maladie r\u00e9siduelle minimale (MRM) en vue de l\u2019attribution du traitement. clonoSEQ est un test de MRM approuv\u00e9 par la FDA qui offre une plus grande sensibilit\u00e9 ( 10<sup>-6<\/sup> c. 10<sup>-5<\/sup>), un taux plus faible de r\u00e9sultats ind\u00e9terminants (\u22645\u00a0% c. 15\u00a0%) et la capacit\u00e9 de capturer l\u2019\u00e9volution clonale au fil du temps \u2013 tout en \u00e9tant moins laborieux et en ayant un d\u00e9lai d\u2019ex\u00e9cution plus rapide \u2013 par rapport au test conventionnel utilis\u00e9 pour d\u00e9tecter et surveiller la MRM chez les patients atteints de LLA (l\u2019essai Ig\/TCR PCR MRM). Bien que clonoSEQ soit r\u00e9guli\u00e8rement rembours\u00e9 par les fournisseurs d\u2019assurance aux \u00c9tats-Unis, il n\u2019est actuellement pas couvert au Canada.<\/p>\n<p>Gr\u00e2ce au soutien d\u2019ACCESS, les patients admissibles au Canada pourront acc\u00e9der au test de MRM clonoSEQ SGN et, par cons\u00e9quent, participer \u00e0 cet essai clinique \u00e0 fort impact qui ouvre une nouvelle voie dans le traitement des patients atteints de LLA-B de classe ABL de type Ph<sup>+ <\/sup>ou Ph. Le C17 Council agira \u00e0 titre de promoteur r\u00e9glementaire canadien de l\u2019essai et lancera l\u2019essai dans les 16\u00a0centres d\u2019oncologie p\u00e9diatrique au Canada.<\/p>\n<p>ACCESS a \u00e9galement soutenu la r\u00e9alisation d\u2019une \u00e9tude corr\u00e9lative int\u00e9gr\u00e9e, qui sera dirig\u00e9e par le D<sup>r<\/sup>\u00a0Thai Hoa Tran du CHU Sainte-Justine, qui \u00e9valuera la corr\u00e9lation entre les niveaux d\u2019ITK et les r\u00e9sultats. Par cons\u00e9quent, en plus de permettre aux patients canadiens de participer \u00e0 l\u2019essai AALL2131 en leur donnant acc\u00e8s \u00e0 des tests sophistiqu\u00e9s et de pointe, le soutien d\u2019ACCESS \u00e0 cet essai au Canada permet \u00e9galement aux chercheurs canadiens\u00a0:<\/p>\n<ol>\n<li>d\u2019\u00e9tablir et d\u2019occuper des postes de direction dans des consortiums internationaux d\u2019oncologie p\u00e9diatrique;<\/li>\n<li>de collaborer avec ces consortiums existants pour mener d\u2019autres recherches cliniques et translationnelles novatrices.<\/li>\n<\/ol>\n<h4 style=\"color: #6251d3;\">Partenaires financiers :<\/h4>\n<p><a href=\"https:\/\/www.childrensoncologygroup.org\/\" target=\"_blank\" rel=\"noopener\">Children&rsquo;s Oncology Group.<\/a><\/p>\n<p><strong><span class=\"info-provided-title\">ClinicalTrials.gov ID: <\/span><a href=\"https:\/\/clinicaltrials.gov\/study\/NCT06124157?term=AALL2131&amp;rank=1\"><i class=\"icon-display\" tabindex=\"0\" title=\"Opens glossary for clinicaltrials.gov identifier (nct number)\" aria-hidden=\"false\" aria-label=\"opens glossary for clinicaltrials.gov identifier (nct number)\" data-term=\"clinicaltrials.gov identifier (nct number)\"><\/i><span class=\"padding-left-05\">NCT06124157<\/span><\/a><\/strong><\/p>\n","protected":false},"author":6,"featured_media":0,"parent":0,"template":"","meta":{"_acf_changed":false,"_monsterinsights_skip_tracking":false,"_monsterinsights_sitenote_active":false,"_monsterinsights_sitenote_note":"","_monsterinsights_sitenote_category":0},"tags":[],"project-category":[126],"class_list":["post-3757","theme-project","type-theme-project","status-publish","hentry","project-category-essais-cliniques"],"acf":[],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.0 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>L\u2019essai  AALL2131  - Access<\/title>\n<meta name=\"description\" content=\"ACCESS is organized into seven research themes from understanding cancer development to its diagnosis, treatment, and survivorship and two cross-cutting groups to support all thematic areas.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"http:\/\/www.accessforkidscancer.ca\/fr\/projects\/lessai\/\" \/>\n<meta property=\"og:locale\" content=\"fr_FR\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"L\u2019essai  AALL2131  - Access\" \/>\n<meta property=\"og:description\" content=\"ACCESS is organized into seven research themes from understanding cancer development to its diagnosis, treatment, and survivorship and two cross-cutting groups to support all thematic areas.\" \/>\n<meta property=\"og:url\" content=\"http:\/\/www.accessforkidscancer.ca\/fr\/projects\/lessai\/\" \/>\n<meta property=\"og:site_name\" content=\"Access\" \/>\n<meta property=\"article:modified_time\" content=\"2025-12-12T17:16:08+00:00\" \/>\n<meta property=\"og:image\" content=\"http:\/\/www.accessforkidscancer.ca\/wp-content\/uploads\/2024\/08\/access-site-image.jpg\" \/>\n\t<meta property=\"og:image:width\" content=\"1200\" \/>\n\t<meta property=\"og:image:height\" content=\"675\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:site\" content=\"@acces_access\" \/>\n<meta name=\"twitter:label1\" content=\"Dur\u00e9e de lecture estim\u00e9e\" \/>\n\t<meta name=\"twitter:data1\" content=\"3 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\/\/schema.org\",\"@graph\":[{\"@type\":\"WebPage\",\"@id\":\"http:\/\/www.accessforkidscancer.ca\/fr\/projects\/lessai\/\",\"url\":\"http:\/\/www.accessforkidscancer.ca\/fr\/projects\/lessai\/\",\"name\":\"L\u2019essai AALL2131 - Access\",\"isPartOf\":{\"@id\":\"https:\/\/www.accessforkidscancer.ca\/fr\/#website\"},\"datePublished\":\"2025-05-29T14:06:25+00:00\",\"dateModified\":\"2025-12-12T17:16:08+00:00\",\"description\":\"ACCESS is organized into seven research themes from understanding cancer development to its diagnosis, treatment, and survivorship and two cross-cutting groups to support all thematic areas.\",\"breadcrumb\":{\"@id\":\"http:\/\/www.accessforkidscancer.ca\/fr\/projects\/lessai\/#breadcrumb\"},\"inLanguage\":\"fr-FR\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"http:\/\/www.accessforkidscancer.ca\/fr\/projects\/lessai\/\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"http:\/\/www.accessforkidscancer.ca\/fr\/projects\/lessai\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"http:\/\/www.accessforkidscancer.ca\/fr\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"L\u2019essai AALL2131\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\/\/www.accessforkidscancer.ca\/fr\/#website\",\"url\":\"https:\/\/www.accessforkidscancer.ca\/fr\/\",\"name\":\"ACCESS\",\"description\":\"Advancing Childhood Cancer Experience, Science &amp; Survivorship\",\"publisher\":{\"@id\":\"https:\/\/www.accessforkidscancer.ca\/fr\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\/\/www.accessforkidscancer.ca\/fr\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"fr-FR\"},{\"@type\":\"Organization\",\"@id\":\"https:\/\/www.accessforkidscancer.ca\/fr\/#organization\",\"name\":\"ACCESS\",\"url\":\"https:\/\/www.accessforkidscancer.ca\/fr\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"fr-FR\",\"@id\":\"https:\/\/www.accessforkidscancer.ca\/fr\/#\/schema\/logo\/image\/\",\"url\":\"https:\/\/www.accessforkidscancer.ca\/wp-content\/uploads\/2024\/08\/access-organization-logo.png\",\"contentUrl\":\"https:\/\/www.accessforkidscancer.ca\/wp-content\/uploads\/2024\/08\/access-organization-logo.png\",\"width\":696,\"height\":696,\"caption\":\"ACCESS\"},\"image\":{\"@id\":\"https:\/\/www.accessforkidscancer.ca\/fr\/#\/schema\/logo\/image\/\"},\"sameAs\":[\"https:\/\/x.com\/acces_access\",\"https:\/\/www.instagram.com\/access_acces\/\",\"https:\/\/www.linkedin.com\/company\/access-acces\/\",\"https:\/\/www.youtube.com\/channel\/UC0SYgen8vfGlXtikQ8xtQ6A\"]}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"L\u2019essai  AALL2131  - Access","description":"ACCESS is organized into seven research themes from understanding cancer development to its diagnosis, treatment, and survivorship and two cross-cutting groups to support all thematic areas.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"http:\/\/www.accessforkidscancer.ca\/fr\/projects\/lessai\/","og_locale":"fr_FR","og_type":"article","og_title":"L\u2019essai  AALL2131  - Access","og_description":"ACCESS is organized into seven research themes from understanding cancer development to its diagnosis, treatment, and survivorship and two cross-cutting groups to support all thematic areas.","og_url":"http:\/\/www.accessforkidscancer.ca\/fr\/projects\/lessai\/","og_site_name":"Access","article_modified_time":"2025-12-12T17:16:08+00:00","og_image":[{"width":1200,"height":675,"url":"http:\/\/www.accessforkidscancer.ca\/wp-content\/uploads\/2024\/08\/access-site-image.jpg","type":"image\/jpeg"}],"twitter_card":"summary_large_image","twitter_site":"@acces_access","twitter_misc":{"Dur\u00e9e de lecture estim\u00e9e":"3 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"WebPage","@id":"http:\/\/www.accessforkidscancer.ca\/fr\/projects\/lessai\/","url":"http:\/\/www.accessforkidscancer.ca\/fr\/projects\/lessai\/","name":"L\u2019essai AALL2131 - Access","isPartOf":{"@id":"https:\/\/www.accessforkidscancer.ca\/fr\/#website"},"datePublished":"2025-05-29T14:06:25+00:00","dateModified":"2025-12-12T17:16:08+00:00","description":"ACCESS is organized into seven research themes from understanding cancer development to its diagnosis, treatment, and survivorship and two cross-cutting groups to support all thematic areas.","breadcrumb":{"@id":"http:\/\/www.accessforkidscancer.ca\/fr\/projects\/lessai\/#breadcrumb"},"inLanguage":"fr-FR","potentialAction":[{"@type":"ReadAction","target":["http:\/\/www.accessforkidscancer.ca\/fr\/projects\/lessai\/"]}]},{"@type":"BreadcrumbList","@id":"http:\/\/www.accessforkidscancer.ca\/fr\/projects\/lessai\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"http:\/\/www.accessforkidscancer.ca\/fr\/"},{"@type":"ListItem","position":2,"name":"L\u2019essai AALL2131"}]},{"@type":"WebSite","@id":"https:\/\/www.accessforkidscancer.ca\/fr\/#website","url":"https:\/\/www.accessforkidscancer.ca\/fr\/","name":"ACCESS","description":"Advancing Childhood Cancer Experience, Science &amp; Survivorship","publisher":{"@id":"https:\/\/www.accessforkidscancer.ca\/fr\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.accessforkidscancer.ca\/fr\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"fr-FR"},{"@type":"Organization","@id":"https:\/\/www.accessforkidscancer.ca\/fr\/#organization","name":"ACCESS","url":"https:\/\/www.accessforkidscancer.ca\/fr\/","logo":{"@type":"ImageObject","inLanguage":"fr-FR","@id":"https:\/\/www.accessforkidscancer.ca\/fr\/#\/schema\/logo\/image\/","url":"https:\/\/www.accessforkidscancer.ca\/wp-content\/uploads\/2024\/08\/access-organization-logo.png","contentUrl":"https:\/\/www.accessforkidscancer.ca\/wp-content\/uploads\/2024\/08\/access-organization-logo.png","width":696,"height":696,"caption":"ACCESS"},"image":{"@id":"https:\/\/www.accessforkidscancer.ca\/fr\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/x.com\/acces_access","https:\/\/www.instagram.com\/access_acces\/","https:\/\/www.linkedin.com\/company\/access-acces\/","https:\/\/www.youtube.com\/channel\/UC0SYgen8vfGlXtikQ8xtQ6A"]}]}},"_links":{"self":[{"href":"http:\/\/www.accessforkidscancer.ca\/fr\/wp-json\/wp\/v2\/theme-project\/3757","targetHints":{"allow":["GET"]}}],"collection":[{"href":"http:\/\/www.accessforkidscancer.ca\/fr\/wp-json\/wp\/v2\/theme-project"}],"about":[{"href":"http:\/\/www.accessforkidscancer.ca\/fr\/wp-json\/wp\/v2\/types\/theme-project"}],"author":[{"embeddable":true,"href":"http:\/\/www.accessforkidscancer.ca\/fr\/wp-json\/wp\/v2\/users\/6"}],"wp:attachment":[{"href":"http:\/\/www.accessforkidscancer.ca\/fr\/wp-json\/wp\/v2\/media?parent=3757"}],"wp:term":[{"taxonomy":"post_tag","embeddable":true,"href":"http:\/\/www.accessforkidscancer.ca\/fr\/wp-json\/wp\/v2\/tags?post=3757"},{"taxonomy":"project-category","embeddable":true,"href":"http:\/\/www.accessforkidscancer.ca\/fr\/wp-json\/wp\/v2\/project-category?post=3757"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}